Blog
Featured post
Truveta Data includes linked closed claims for over 200 million patients
By linking complete clinical data with comprehensive claims records, Truveta advances real-world evidence (RWE) generation that can replace, or complement, clinical trials and registries.
GLP-1 RA prescription trends: January 2018 – December 2024
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in December 2024 were similar to September 2024 (+1.89%). Anti-diabetic medication (ADM) prescribing...
Real-world insights on heart failure recovery: A missed opportunity in guideline-directed therapy
Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of morbidity and mortality. While guideline-directed medical therapy (GDMT) has been shown to improve...
Analysis of real-world treatment of epilepsy using Truveta Data
Recently, researchers presented new epilepsy research at the American Epilepsy Society Annual Meeting in Los Angeles, California. Using Truveta Data, the researchers explored two...
Advancing cardiovascular device research with Truveta Data
The need for better cardiovascular device insights Medical device companies are at the forefront of innovation, but a lack of real-world clinical data (RWD) hampers progress in...
Real-time monitoring of respiratory virus-associated hospitalizations: Trends through January 2025
Influenza continues to be on the rise. Influenza-related hospitalizations increased by 53.7% and now are associated with 6.8% of all hospitalizations. For kids aged 4 and younger...
Truveta Data grows to include linked closed claims for more than 200 million patients
Truveta Data has now expanded to include new commercial, Medicare, and Medicaid closed claims on more than 200 million patients, linked with electronic health record (EHR) data...
How real-world data is unlocking mental health
Understanding mental health prescribing trends
Mental health prescribing remained relatively stable since 2018. Prescription rates for antidepressants, mood stabilizers, and antipsychotics peaked between 2020 and 2022 but...
GLP-1 discontinuation and reinitiation trends study published in JAMA Network Open
Discontinuation within one year was significantly higher in patients without T2D (64.8%) compared to those with T2D (46.5%). When patients experienced greater weight loss, they...